Welcome to our dedicated page for Conavi Medical news (Ticker: CNVIF), a resource for investors and traders seeking the latest updates and insights on Conavi Medical stock.
Conavi Medical Corp. (CNVIF) is a commercial-stage medical device company focused on intravascular and intracoronary imaging technologies used during minimally invasive cardiovascular procedures. Its news flow centers on the development, regulatory progress, and commercialization of the Novasight Hybrid™ System, a patented platform that combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single system for simultaneous, co-registered imaging of coronary arteries.
On this page, readers can follow company announcements related to the Novasight Hybrid™ platform, including updates on the next-generation Novasight Hybrid™ IVUS/OCT intravascular imaging system and its submission to the U.S. Food and Drug Administration (FDA) for 510(k) clearance for coronary applications. Conavi’s news often highlights validation testing with interventional cardiologists, participation in major cardiology conferences such as Transcatheter Cardiovascular Therapeutics (TCT), and educational sessions on hybrid IVUS/OCT imaging in complex percutaneous coronary interventions (PCI).
Investors and clinicians can also track peer-reviewed publication highlights referenced by Conavi, including case reports and large-scale analyses that discuss the role of intravascular imaging in PCI, as well as commentary on international guideline updates that recommend IVUS or OCT guidance in complex coronary cases. Financial and corporate news items may cover public equity financings, non-dilutive funding agreements such as the Life Sciences Scale-Up Fund in Ontario, and leadership or organizational updates that the company associates with its commercialization plans.
By monitoring this CNVIF news feed, users can see how Conavi describes the evolution of its hybrid imaging technology, its regulatory milestones, and its efforts to prepare manufacturing and operational infrastructure for broader clinical use of the Novasight Hybrid™ System.
Conavi Medical (OTCQB: CNVIF) reported Fiscal Q1 2026 results for the quarter ended Dec 31, 2025, and highlighted operational developments. Key items: $12.0M public equity offering closed Jan 13, 2026; anticipated U.S. FDA 510(k) clearance in H1 2026; peer‑reviewed publication supporting hybrid IVUS‑OCT imaging; and termination of a $270,000 loan via issuance of 75,000 shares.
Financials: total revenue was $0.2M (prior $8.6M), operating loss $5.1M, net loss $2.7M ($0.04/share), and cash was $1.0M at quarter end before the subsequent $12.0M financing.
Conavi Medical (OTC:CNVIF) highlighted a peer‑reviewed Cardiovascular Research publication (Feb 2026) showing a histology‑trained hybrid IVUS‑OCT deep‑learning classifier outperformed single‑modality IVUS, OCT, and expert readers in plaque characterization. The company said this supports clinical and commercial value for its hybrid platform and noted it has submitted its next‑generation Novasight system to the FDA. The release also disclosed a 1,000,000 stock option grant to CFO Mark Quick at a $0.41 exercise price (VWAP on Feb 10, 2026), subject to vesting, expiry and regulatory approvals.
Conavi Medical (OTCQB: CNVIF) reported fiscal 2025 results for the year ended Sept 30, 2025 and provided an operational update ahead of a planned U.S. commercial launch. Key business highlights include a 510(k) submission for the next-generation Novasight Hybrid™ IVUS/OCT system, participation at major cardiology conferences, multiple peer-reviewed publications supporting image-guided PCI, and leadership hires to support U.S. scale-up.
Financially, revenue was $9.1M (FY2025) vs $2.2M (FY2024); net loss was $20.5M or $0.36/share; cash was $5.8M. The company completed a $20M public equity financing and is eligible for up to $2.5M in non-dilutive funding.
Conavi Medical (OTC:CNVIF) announced leadership changes and U.S. commercialization preparations on November 3, 2025. The company appointed Mark Quick as Chief Financial Officer to lead financial strategy and investor engagement, while current CFO Stefano Picone moves to a transitional Chief Strategy Officer role to support continuity during scale-up.
Conavi also submitted its next‑generation Novasight Hybrid IVUS/OCT intravascular imaging system to the U.S. FDA for 510(k) clearance and said it is building U.S. commercial infrastructure ahead of launch.
Conavi Medical (OTCQB: CNVIF) announced on October 29, 2025 an agreement with the Province of Ontario under the Life Sciences Scale-Up Fund to support the commercial launch of the next‑generation Novasight Hybrid system.
Under the arrangement Conavi is eligible to receive up to $2.5 million CAD over the project to cover up to one‑third of eligible project costs, subject to certain requirements. The funding is intended to support design and manufacturing activity for the dual‑modality intravascular imaging system that combines IVUS and OCT to guide coronary procedures.
Conavi Medical (OTCQB: CNVIF) will highlight its Novasight Hybrid™ intravascular imaging at TCT 2025 in San Francisco, Oct 25–28, 2025, with booth #2126.
The company will present clinical images from its first‑generation IVUS/OCT system and participate in physician‑led Intravascular Imaging & Training sessions on Oct 26–27. Conavi said the next‑generation Novasight Hybrid was submitted for FDA 510(k) clearance in September 2025. The first‑generation system previously received FDA 510(k) clearance, Health Canada approval, and was used at seven luminary cardiovascular hospitals in North America.
Conavi Medical (OTCQB: CNVIF) will present at the Planet MicroCap Showcase: TORONTO in partnership with MicroCapClub on Wednesday, October 22, 2025 at 9:30 AM EST at the Arcadian Loft in Downtown Toronto.
Tom Looby, Chief Executive Officer, will host the presentation and take questions. A live webcast will be available and all company webcasts will be archived on the event platform under the Agenda tab. Investors may register to attend and request 1x1 in-person meetings at the conference venue.
Conavi Medical (OTCQB: CNVIF) has submitted its next-generation Novasight Hybrid™ IVUS/OCT intravascular imaging system to the FDA for 510(k) clearance. The system uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in a single integrated platform for coronary applications.
Key improvements include enhanced image quality, simplified user interface, improved cath lab workflow, and increased reliability. The company anticipates FDA clearance during H1 2026 and is preparing for US commercial launch. The coronary intravascular imaging market is projected to exceed $1 billion USD by 2028, supported by recent class IA guidelines in both US and Europe recommending IVUS or OCT for PCI procedural guidance.
Conavi Medical (OTCQB:CNVIF), a medical device company specializing in cardiovascular imaging technology, reported its fiscal Q3 2025 results and provided key operational updates. The company remains on track to submit its 510(k) application for the Novasight Hybrid™ system to the FDA in Q3 2025, targeting a commercial launch in H1 2026.
Financial highlights include a significant reduction in operating loss to $4.6M from $8.9M year-over-year, and improved cash position of $11.3M following a $20M equity offering completed in April. Revenue was $63,000, down from $401,000 in the prior year, reflecting the company's focus on next-generation product development.
Operational achievements include successful validation testing with leading cardiologists and a notable publication in JSCAI validating their hybrid IVUS/OCT imaging approach.
Conavi Medical (OTCQB: CNVIF) announced the publication of a significant case report in the Journal of the Society for Cardiovascular Angiography & Interventions featuring their Novasight™ Hybrid IVUS-OCT System. The case report demonstrates how the system's dual imaging capabilities led to superior diagnosis and treatment in a complex coronary case.
The study highlighted how the system correctly identified a plaque rupture that was initially misdiagnosed as calcification through traditional angiography. The technology combines high-resolution OCT imaging with IVUS anatomical reference points, enabling precise stent placement. CEO Thomas Looby confirmed the company's next-generation Novasight™ Hybrid System is on track for FDA 510(k) submission in Q3 2025.